Pimavanserin + Placebo
Phase 2/3Completed 0 watching 0 views this week📈 Rising
60
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Irritability Associated With Autism Spectrum Disorder
Conditions
Irritability Associated With Autism Spectrum Disorder
Trial Timeline
Aug 9, 2022 → Sep 27, 2024
NCT ID
NCT05523895About Pimavanserin + Placebo
Pimavanserin + Placebo is a phase 2/3 stage product being developed by Acadia Pharmaceuticals for Irritability Associated With Autism Spectrum Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT05523895. Target conditions include Irritability Associated With Autism Spectrum Disorder.
Hype Score Breakdown
Clinical
22
Activity
15
Company
5
Novelty
7
Community
8
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05523895 | Phase 2/3 | Completed |
| NCT04531982 | Phase 3 | Completed |
| NCT03968159 | Phase 3 | Completed |
| NCT03575052 | Phase 3 | Completed |
| NCT02970305 | Phase 2 | Completed |
| NCT02970292 | Phase 3 | Completed |
Competing Products
7 competing products in Irritability Associated With Autism Spectrum Disorder
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| KarXT + KarX-EC + KarXT + KarX-EC Matching Placebo | Bristol Myers Squibb | Phase 3 | 76 |
| KarXT + KarX-EC + KarXT + KarX-EC Matching Placebo | Bristol Myers Squibb | Phase 3 | 76 |
| Aripiprazole + Placebo | Bristol Myers Squibb | Approved | 84 |
| Brexpiprazole + Placebo | Lundbeck | Phase 3 | 74 |
| Brexpiprazole | Lundbeck | Phase 3 | 74 |
| JZP541 | Jazz Pharmaceuticals | Phase 2 | 49 |
| Pimavanserin | Acadia Pharmaceuticals | Phase 2/3 | 60 |